T A B L E O F C O N T E N

Death
B A C K G R O U N D
Provision of combination antiretroviral treatment (ART) to people infected with human immunodeficiency virus (HIV) reduces both progression to the acquired immunodeficiency syndrome (AIDS) and the morbidity and mortality associated with advanced HIV infection. According to consensus, initiation of therapy is best based on CD4 count, a marker of immune status, rather than on viral load, a marker of virologic replication (Sterling 2001) . For patients with advanced symptoms, treatment should be started regardless of CD4 count; however, the point during the course of HIV infection at which ART is best initiated in asymptomatic patients remains unclear, and in a 2006 BMJ review, Deeks clearly articulated optimal timing of ART initiation as a key unanswered question for people infected with HIV, clinicians, and policy-makers (Deeks 2006) .
Guidelines issued by various agencies provide different initiation recommendations according to resource availability. This can be confusing for clinicians and policy-makers when they are determining the best time to initiate therapy. In 2008, the United States Panel of the International AIDS Society recommended that ART in adults with HIV infection should not be initiated before CD4 cell count declines to less than 350 cells/µL (Hammer 2008) . In patients with 350 CD4 cells/µL or more, the decision to begin therapy should be individualized based on the presence of comorbidities, risk factors for progression to AIDS and non-AIDS defining diseases (Hammer 2008) . In comparison, in resource-constrained settings, the World Health Organization recommends that ART should not be initiated at concentrations of CD4 counts above 200 cells/µL in asymptomatic patients (WHO 2006) and does not address initiation at higher concentration of CD4 cells. Optimizing the initiation of ART is clearly complex and must, therefore, be balanced between individual and broader public health needs.
Historically, clinicians determined initiation of ART by balancing the risks and benefits of delaying treatment (Sabin 2009). Original ART formulations had high pill counts, inconvenient dosing instructions and often substantial toxicities which favoured a delay in treatment to avoid poor adherence early in the disease. Currently there are better-tolerated ART formulations and an increase in the number of treatment options available (Schrader 2008) . Additionally, targeted adherence interventions have been shown to be associated with high adherence rates (Orrell 2007) . Initiating early treatment has the benefit of reducing or avoiding the irreversible damage done by HIV and opportunistic infections (OIs) (Day 2002) . Treating patients at higher CD4 counts may reduce infectivity and so play an important role in community prevention, although this has not been proved conclusively (Granich 2009 
O B J E C T I V E S
To assess the evidence for the optimal time to initiate ART in treatment-naive, asymptomatic, HIV-infected adults
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials
Types of participants
Asymptomatic, HIV-infected, treatment-naive adults (15 years of age and older) Trials of participants co-infected with hepatitis B or C were not excluded from this review. Trials of participants who are symptomatic regardless of CD4 counts were excluded from this review. Trials of initiation of ART in participants co-infected with tuberculosis (TB) were excluded from this review as a concurrent Cochrane review is being conducted on this topic.
Types of interventions
ART consisting of three drugs initiated early in the disease at high CD4 counts, as defined by the trial. In adults, the definition of high count may be at levels of 201-350, 351-500 or >500 cells/ µL. The comparison group will be when ART is initiated at CD4 counts below 200 cells/µL, or as defined by the trial. 
Types of outcome measures
Search methods for identification of studies
See: HIV/AIDS Collaborative Review Group search strategy
Electronic searches
We developed the search strategy with the assistance of the HIV/ AIDS Review Group Trials Search Co-ordinator. We formulated a comprehensive and exhaustive search strategy in an attempt to identify all relevant studies regardless of language or publication status (published, unpublished, in press , and in progress). Full details of the Cochrane HIV/AIDS Review Group methods and the journals hand-searched are published in the section on Collaborative Review Groups in The Cochrane Library. We combined the RCT strategy developed by The Cochrane Collaboration and detailed in the Cochrane Reviewers' Handbook (Higgins 2008) in combination with terms specific to initiation of ART. We limited the date-of-publication year to 1996 onwards because triple-drug ART was not used before this year. The search was iterative and a number of trial searches were run first as there are no database-specific terms for 'initiation' of treatment and so we used many freetext terms. This increased the yield and hence the search sensitivity but reduced the precision. We searched the following electronic databases:
1.
Journal and trial databases MEDLINE This search was conducted on 4 August 2009 using the strategy outlined in Table 1 . This yielded 1389 records of which we identified 42 records for full article retrieval. Table 2 . This yielded 547 records of which we identified 12 records for full article retrieval. Table 3 . The search yielded 424 records of which we identified 11 records for full article retrieval. Table 3 . Search strategy for CENTRAL Conference databases: We searched NLM Gateway on 4 August 2009 using the strategy outlined in Table 4 . NLM Gateway covers abstracts from a number of relevant international conferences, including the International AIDS Conference, Conference on Retroviruses and Opportunistic Infections, The British HIV Association Conference and the International Congress on Drug Therapy in HIV infection. The search yielded 2666 records of which 94 records were categorised as Meeting Abstracts and of which eight were identified for full article retrieval. (2001, 2003) , using the search terms "when to start" OR ("early" AND "initia*") in any field. This retrieved 89 records from which we identified no RCTs (we attempted to retrieve full reports for nine abstract records but only for the purposes of background literature).
ID Search Hits
#1 (HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HU-MAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IM-MUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND ( DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODE-FICIENCY SYNDROME) OR (ACQUIRED IMMUNED-EFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IM-MUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED
We also attended the International AIDS Society conference held in Cape Town, South Africa in July 2009 and identified one relevant study presented as a late-breaker study (CIPRAHT001 2009).
3.
Ongoing trials: We searched ClinicalTrials.gov (http://clinicaltrials.gov/) (70 records identified and five for download) and the Pan-African Clinical Trials Registry (www.pactr.org) for HIV-related records (seven in total) but found no relevant records for download.
Searching other resources
Researchers and relevant organizations
We were in close contact with individual researchers working in the field and policymakers based in inter-governmental organizations including the WHO.
2.
Reference lists We also checked the reference lists of all studies identified by the above methods and examined any systematic reviews, meta-analyses, or prevention guidelines we identified during the search process for references.
Data collection and analysis
Selection of studies NS and OU read the titles, abstracts and descriptor terms of all downloaded material from the electronic searches to identify potentially eligible reports. Full text articles were obtained for all citations identified as potentially eligible and NS and OU independently inspected these to establish the relevance of the article according to the pre-specified criteria. Where there was any uncertainty as to the eligibility of the record, we obtained the full article. NS and UO independently applied the inclusion criteria, and any differences arising were resolved by discussions with the third reviewer, GR. Studies were reviewed for relevance based on study design, types of participants, exposures and outcome measures.
Data extraction and management
NS and UO independently extracted data into a standardised data extraction form. The following characteristics were extracted from each included study:
• Administrative details: Trial identification number; author(s); published or unpublished; year of publication; number of studies included in paper; year in which study was conducted; details of other relevant papers cited;
• Details of the study: study design; type, duration and completeness of follow-up; country and location of study (e.g. higher-income vs. lower-income country); informed consent and ethics approval;
• Details of participants: setting, numbers, relevant baseline characteristics including CD4 count and viral load;
• Details of intervention: CD4 count at which treatment was initiated; drug combinations; additional co-interventions; and
• Details of outcomes: mortality; HIV-related morbidity; HIV-RNA viral load measurements and proposed levels for suppression, as defined by the authors; CD4+ cell counts; adverse events and toxicity.
Assessment of risk of bias in included studies
NS and OU independently examined the components of each included trial for risk of bias using a standard form. This included information on the sequence generation, allocation concealment, blinding (participants, personnel and outcome assessor), incomplete outcome data, selective outcome reporting and other sources of bias. The methodological components of the trials were assessed and classified as adequate, inadequate or unclear as per the Cochrane Handbook of Systematic Reviews of Interventions (Higgins 2008). Where differences arose, they were resolved by discussions with the third reviewer, GR.
Sequence generation
• Adequate: investigators described a random component in the sequence generation process such as the use of random number table, coin tossing, cards or envelops shuffling, etc
• Inadequate: investigators described a non-random component in the sequence generation process such as the use of odd or even date of birth, algorithm based on the day/date of birth, hospital or clinic record number
• Unclear: insufficient information to permit judgment of the sequence generation process
Allocation concealment
• Adequate: participants and the investigators enrolling participants cannot foresee assignment (e.g. central allocation; or sequentially numbered, opaque, sealed envelopes)
• Inadequate: participants and investigators enrolling participants can foresee upcoming assignment (e.g. an open random allocation schedule (e.g. a list of random numbers); or envelopes were unsealed or nonopaque or not sequentially numbered)
• Unclear: insufficient information to permit judgment of the allocation concealment or the method not described
Blinding
• Adequate: blinding of the participants, key study personnel and outcome assessor, and unlikely that the blinding could have been broken. Or lack of blinding unlikely to introduce bias. No blinding in the situation where non-blinding is not likely to introduce bias.
• Inadequate: no blinding, incomplete blinding and the outcome is likely to be influenced by lack of blinding
• Unclear: insufficient information to permit judgment of adequacy or otherwise of the blinding
Incomplete outcome data
• Adequate: no missing outcome data, reasons for missing outcome data unlikely to be related to true outcome, or missing outcome data balanced in number across groups
• Inadequate: reason for missing outcome data likely to be related to true outcome, with either imbalance in number across groups or reasons for missing data
• Unclear: insufficient reporting of attrition or exclusions
Selective Reporting
• Adequate: a protocol is available which clearly states the primary outcome as the same as in the final trial report
• Inadequate: the primary outcome differs between the protocol and final trial report
• Unclear: no trial protocol is available or there is insufficient reporting to determine if selective reporting is present
Other forms of bias
• Adequate: there is no evidence of bias from other sources • Inadequate: there is potential bias present from other sources (e.g. early stopping of trial, fraudulent activity, extreme baseline imbalance or bias related to specific study design)
• Unclear: insufficient information to permit judgment of adequacy or otherwise of other forms of bias
Measures of treatment effect
Data analysis was conducted using Review Manager (RevMan) version 5.0.15 (2008) . Outcome measures for dichotomous data (e.g. death, virologic suppression) were calculated as a relative risk with 95% confidence intervals. We had planned to calculate continuous data (e.g. CD4+ cell counts, HIV-RNA viral loads) using the weighted mean difference and standard deviations but at time of writing we did not have access to any of these data.
Assessment of heterogeneity
Where trials were found to be methodologically or clinically comparable, we pooled trial results in a meta-analysis. As we anticipated the presence of statistical heterogeneity we combined data using the random effects model . We formally tested for statistical heterogeneity using the Chi-square test for statistical homogeneity with a 10% level of significance as the cut-off. The impact of any statistical heterogeneity was quantified using the I² statistic (Higgins 2002). Where studies do not have combinable outcomes, we provide the data in a narrative form.
Subgroup analysis and investigation of heterogeneity
We anticipated statistical heterogeneity due to differences between trials conducted in resource-constrained compared with resourcerich settings, and planned to present the results according to these sub-groups. However, as only two trials were identified we did not undertake this analysis. We also planned to present trials of participants co-infected with hepatitis B or C viruses as a subgroup, but no such trials were identified.
Sensitivity analysis
We planned to explore the effect of trial quality on the results by excluding those trials where allocation concealment was unclear or inadequate from the meta-analysis and assessing the effect of this on the overall results. experimental drug conservation strategy. The results for a sub-set of those participants within the larger trial who were treatmentnaive are included in this review. This analysis was reported as posthoc and included a group of participants who were either ARTnaive or who had received ART and ceased to take it 6 months prior to enrollment. For this review we report the results only for those ART-naive participants. The analysis of the sub-set differs slightly from that of the CIPRAHT001 2009 trial in that it compared starting ART at 350 cells/µL with starting ART at 250 cells/µL.
Excluded studies
Reasons for excluding studies during the search are summarised in Figure 1 . One study (Erhabor 2006) was reported as a randomised trial but further email discussion with the authors confirmed it was a stratified cohort study.
Risk of bias in included studies
See Figure 2 and Figure 3 for a graphical representation of the risk of bias in both trials. 
Allocation
Generation of the random sequence was by computer and allocation concealment was done centrally so we judged both random generation and allocation concealment to be adequate for the CIPRAHT001 2009 and not likely to introduce bias. Neither the method of generation nor the method of allocation concealment was clearly reported for the SMART 2008 trial, although blocked stratification was used and was likely to be done by computer. As the analysis reported her is for a sub-group within randomized groups, there is a possible potential for bias but this is unlikely to be due to the method of randomization.
Blinding
In both trials the deferred groups were not provided with placebo and the participants and providers were therefore not blinded. Although in the CIPRAHT001 2009 trial, the investigators and members of the protocol team were blinded to the randomisation groups, we assessed the risk for bias from blinding to be moderate due to the lack of placebo. Similarly in the SMART 2008 trial the assessors in the end-point committee were blinded to the randomized groups and so we assessed the risk to be moderate.
Incomplete outcome data
Attrition was low and less than 10% in both trials at the time the trials were stopped. However, we rated the risk of bias due to incomplete outcome reporting as moderate in both trials as acceptable statistical survival analysis techniques were used to estimate HIV event distribution over time by accumulating for staggered enrolment and incomplete discrete follow-up.
Selective reporting
Both trial reports compare favourably with the protocols published on www.clinicaltrials.gov and so the risk of bias is likely to be low from selective reporting.
Other potential sources of bias
The CIPRAHT001 2009 trial was stopped early due to significant benefits in the early ART group. Although the reported results make use of survival analyses in an attempt to reduce the risk from bias due to early stopping, we assessed the bias to be moderate because of the early stopping. The results reported here for the SMART 2008 trial could be susceptible to publication bias as the analysis of the ART-naive was post-hoc and it is possible that investigators of other trials may not have conducted post-hoc analyses of similar nested subgroups within their trials. We assessed the risk of bias from this as high. Other anticipated outcomes we identified in our protocol as primary outcomes, were not reported in the two trials and we therefore are not able to provide information on these.
Effects of interventions
SECONDARY OUTCOMES:
None of the anticipated secondary outcomes identified in our protocol were reported in the two trials.
ADVERSE EFFECTS:
Results were only available for CIPRAHT001 2009. For the SMART 2008 trial, the adverse events were not categorized according to the ART-naive participants, and so it was not possible to extract data specific to the sub-group included in this review In CIPRAHT001 2009 there was no statistically significant difference in the number of independent Grade 3 or 4 adverse events occurring in the early and standard ART groups when we conducted an intention-to-treat analysis (i.e. we used the total number of participants randomised into each group as the denominators in both groups with both = 408) (RR = 1.72; 95% CI: 0.98, 3.03; P = 0.06). See Analysis 1.4. When analysing only participants who actually commenced ART in the deferred group (n = 160), the authors report a statistically significant increase in the incidence of zidovudine-related anaemia (8.1%) compared with those in the early initiation group (3.4%) (RR = 0.42; 95% CI: 0.20, 0.88; P = 0.02). See Analysis 1.5.
GRADE ASSESSMENT:
As this review was done as part of a report to inform the WHO's 2009 adults and adolescent ART guideline revisions, we also conducted a GRADE assessment, although this was not stipulated in the protocol. See Summary of findings for the main comparison.
Using the GRADE tool, we evaluated the evidence provided by the RCTs and rated this for each outcome identified as critical or important to determining whether or not to change the current WHO guidelines for timing of initiation of ART. For the critical outcomes of death and TB, we rated the quality of the evidence as moderate. Although the data come from two RCTs, they were down-graded to moderate due to the possibility of publication bias and because the data were obtained from only one high-quality RCT directly aimed at answering the question combined with data from a sub-group nested within a larger trial not directly aimed at answering the question. For the critical outcome of disease progression we rated the evidence as low given that the data were only available from the sub-group nested within the larger trial.
For the critical adverse events we rated the evidence as moderate. In this case, despite the data coming from a high-quality trial, we downgraded the quality of the evidence because it was only obtained from one RCT and could therefore be imprecise. Ideally additional trials would be needed to improve precision. The important outcomes of sexual immunological and virologic response, adherence, tolerance and retention, and HIV drug resistance were not measured in either of the trials.
D I S C U S S I O N
Summary of main results
Pooled data from one trial of 816 participants and one sub-group analysis of 248 participants provide moderate-quality evidence that starting ART at CD4 levels higher than 200 or 250 cells/µL but below 350 cells/µL reduces mortality rates in asymptomatic, ART-naive, HIV-infected people. Evidence regarding a reduction in morbidity is less strong and incidence of severe adverse events is apparently low, but this data is available from only one trial and so must be viewed with caution.
Overall completeness and applicability of evidence
Only the CIPRAHT001 2009 trial directly answered the question of whether starting ART at CD4 levels above 200 cells/µL improves mortality and morbidity (as measured by incidence of TB) compared with the current WHO guideline recommendations of starting at 200 cells/µL (WHO 2006) . This trial was located in a resource-constrained setting and therefore has a high applicability to low-income countries. Full results from this trial have yet to be published, however, and must therefore be viewed as incomplete. There are no available data on follow-up beyond the median of 21 months and no available data on development of possible resistance in those initiating ART. Although we included the results from the SMART 2008 trial in the meta-analysis, these were from a post-hoc analysis of ART-naive participants nested within a larger trial which aimed to provide evidence regarding treatment interruptions rather than optimal timing of ART. For this reason the evidence from the SMART 2008 trial must be interpreted with caution. Ideally, additional trials would strengthen the nature and quality of the above evidence. We identified two ongoing trials (START 2009; NCT00491556) . Both of these trials are being conducted in high-income settings and are comparing initiation of ART at CD4 levels above either 350 cells/µL (NCT00491556) or 500 cells/ µL (START 2009). Although these trials will provide useful data to inform initiating ART at CD4 levels above current guidelines operational in many high-income countries, the data will not add to the evidence base for determining whether initiating ART at levels above current WHO guidelines is optimal compared with initiating at CD4 counts <200 cells/µL. We did not identify and are not aware of any ongoing trials aiming to answer this question apart from the CIPRAHT001 2009 trial, although a number of trials aimed at timing of ART in patients co-infected with TB are underway.
We did not identify any trials which evaluated the effects of optimal initiation of ART in people co-infected with either hepatitis B or C, or both, and evidence for these populations remains limited.
Quality of the evidence
The quality of the methodological conduct for both trials was moderate to high and the risk of bias was likely to be low to moderate for both trials. Caution must be exercised when interpreting the results from the SMART 2008 trial, however, as this was a post-hoc analysis and, as such, may be prone to the effects of publication bias. This would occur if other trials did not conduct or publish similar analyses of potential sub-sets within the original trials. We, however, have no knowledge that this occurred in other trials. Both trials employed early stopping rules considered acceptable statistical practice (Kim 1987) . Use of survival analysis which incorporates the results from all those who completed the trial and who are censored due to loss-to-follow-up or early stopping of the trial, will have reduced the potential for attrition bias in each trial. This was done in both trials, but survival data were not available for the sub-set in the SMART 2008 trial. For this reason, in our meta-analysis we present the proportions at the time of stopping the trial. It is important to note that in a systematic review of RCTs stopped early for benefit, such RCTs were found to overestimate treatment effects (Montori 2005) . When trials with events fewer than the median number (n=66) were compared with those with event numbers above the median, the odds ratio for a magnitude of effect greater than the median was 28 (95% CI: 11,73) (Montori 2005). Both trials included in our review yielded fewer than 66 events and may thus overestimate the treatment effect. The magnitude of effect was consistent across both trials, however, which strengthens the evidence in favour of starting ART earlier than standard WHO guidelines recommend.
Potential biases in the review process
We conducted comprehensive searches of both journal and conference databases to ensure all relevant published and unpublished trials were identified. We did not limit the searches to a specific language. Our ongoing interaction with the investigator of the CIPRAHT001 2009 trial allowed us access to preliminary and unpublished data. Given the high-profile nature of the intervention and the complexity of conducting ART initiation trials, it is unlikely that our search strategy failed to detect existing current trial evidence. Potential bias in the conduct of our review was also minimised by having two independent researchers extract data and assess the methodological quality of each study. This detailed process allows for a thorough assessment of trial conduct and an exploration of the possible biases that may be present in each trial. When we pooled data in the meta-analysis we combined the arms from both trials although these were slightly different because the analysis of the SMART 2008 sub-set compared starting ART at CD4 levels of 350 cells/µL with starting ART at 250 cells/µL, whereas the CIPRAHT001 2009 trial compared starting at CD4 levels of between 200 and 350 cells/µL with starting ART at 200 cells/µL. Given that both trials compared initiating ART at higher levels with deferring the start of ART, we did not consider this difference to be a source of bias, but the evidence must be viewed as less direct.
Agreements and disagreements with other studies or reviews
These results are consistent with previous cohorts from both highand low-income studies which showed that early initiation of ART may reduce morbidity and mortality associated with HIV/ AIDS ( 
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is moderate-quality evidence derived from trials that initiating ART at CD4 levels higher than 200 or 250 cells/µL reduces mortality rates in asymptomatic, ART-naive, HIV-infected people. Practitioners and policy-makers may consider initiating ART at levels ≤350 cells/µL for patients who present to health services and are diagnosed with HIV early in the infection. Evidence for initiating ART in patients co-infected with TB and hepatitis patients remains unclear.
Implications for research
Given that there are two RCTs in the field, future research should focus on long-term cohort studies to collect data on the incidence and nature of adverse effects, and the development of viral resistance, in those initiating ART at higher CD4 levels than previous standard practice. In many resource-constrained settings a remaining challenge is to identify patients sufficiently early in the course of the infection to benefit from early treatment. Research efforts (ideally clinical trials) should investigate interventions to promote voluntary counseling and testing, to reduce the stigma of testing for HIV and to encourage people to present for testing. Costeffectiveness remains an area requiring ongoing investigation. In high-income countries, the results from two ongoing trials comparing initiation of ART at CD4 levels above either 350 cells/µL or 500cells/µL with standards of care will provide necessary evidence for practice in these settings.
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NS wishes to acknowledge the assistance and patience of Eliza Humphreys in co-ordinating the review process and Larry Chang for his careful review. Interventions Intervention: EARLY: Start ART (lamivudine 150mg and zidovudine 300mg in a fixeddose combination twice daily and efavirenz 600mg at night) within two weeks of enrollment. Comparison: STANDARD: Start ART (lamivudine 150mg and zidovudine 300mg in a fixed-dose combination twice daily and efavirenz 600mg at night) when the CD4 cell count is ≤ 200 cells/µL or the patient develops an AIDS-defining illness. Both groups received Trimethoprim-sulfamethoxazole prophylaxis and daily multi-vitamins and monthly food baskets).
C H A R A C T E R I S T I C S O F S T U D I E S
Outcomes PRIMARY OUTCOME Death -documented by one of the following: obituary, autopsy report, hospital death certificate, or contact report documenting verbal communication with the participant's healthcare provider, family member, or significant other. SECONDARY OUTCOME incidence of TB -HIV infected patients with a cough or other symptoms suggestive of tuberculosis are routinely screened at the clinic with a chest radiograph and three sputum smears for acid fast bacilli (AFB) by Ziehl-Neelsen staining and Mycobacterium tuberculosis culture on Lowenstein Jensen media. TB case definition was based upon American Thoracic Society with diagnosis requiring symptoms consistent with tuberculosis and microbiologic confirmation of disease, or symptoms, a chest radiograph consistent with tuberculosis, and a positive response to anti-tuberculosis therapy. ADVERSE EVENTS will need to contact investigators to confirm reported outcomes conform to those in protocol.
Free of other bias? No Stopped early but acceptable statistical stopping rules applied to reduce effects of attrition bias. An O'Brien-Fleming boundary and the Lan-DeMets alpha spending function was used to determine whether to terminate the trial early. The results reported here are not free of bias as the analysis of the ART-naive was post-hoc and it is possible that other studies may not have conducted similar post-hoc analysis so there is a threat of publication bias.
Characteristics of excluded studies [ordered by study ID]
Erhabor 2006 Although the text of the article refers to randomizing patients, email communication with the first author confirmed that this is a stratified cohort study and not an RCT
Characteristics of ongoing studies [ordered by study ID]
NCT00491556
Trial name or title Early initiation of HAART Methods This is a randomized, proof of concept study of youth 18-24 years of age with confirmed HIV after age 9 with CD4+ T cells above 350 cells/mm3 who are randomized 3:1 to begin HAART consisting of TDF/FTC/ ATV/r (preferred), AZT/3TC/ATV/r, or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for two years. Subjects randomized to the standard care arm will begin HAART with TDF/ FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care.
Participants
Age 18 yrs and 0 days to 24 yrs and 364 days with CD4+ T cells >350/mm3 as determined by two consecutive measures within 6 months of entry, with second measure being collected at pre-entry. Infected with HIV after age 9
Interventions Experimental: Subjects in the experimental group will begin HAART consisting of TDF/FTC/ATV/r (preferred), AZT/ 3TC/ATV/r or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an NCT00491556 (Continued) additional two years Control: Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/ 3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/ mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
Outcomes
Primary Outcome: Ability to maintain or enhance HAART-associated quantitative changes in CD4+ T cell percentages achieved during HAART following therapy de-intensification to ATV/r in adolescents and young adults who began treatment prior to meeting DHHS guidelines.
Secondary Outcomes:
• Quantitative and qualitative changes in T cell subsets percentage in those initiating HAART prior to current guidelines followed by de-intensification and in subjects initiating HAART by current DHHS guidelines
• Ability to maintain decreases in T cell activation achieved during HAART following therapy deintensification
• Ability to maintain virologic control following de-intensification in adolescents treated with HAART prior to meeting DHHS guidelines
• Impact of early HAART initiation on thymic output • Determine the emergence of drug resistance in subjects who fail therapy de-intensification • Evaluate the safety of initiating ART prior to significant CD4+ T cell loss with respect to emergence of drug associated toxicity and drug resistance
• Monitor prevalence of genotypic drug resistance within an ARV naïve or minimally exposed adolescent and young adult population; evaluate the associations of subject demographic and clinical variables with presence of genotypic mutation 
Interventions
To determine whether initiation of ART in HIV-infected, treatment-naive persons with CD4 counts > 500 cells/mm 3 is superior in terms of mortality and morbidity to deferral of treatment until the CD4 count declines to < 350 cells/mm 3.
